Side-by-side · Research reference

CrystagenvsPinealon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BHuman-MechanisticAUTO-DRAFTED12/36 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

01Mechanism of Action

Parameter

Crystagen

Pinealon

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

—

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

Pinealon

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

5–10 mg / day for 10 daysKhavinson 2014

Evidence basis

Animal / mechanistic

Russian clinical trials + in vitroKhavinson 2014

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

Once daily during cycle

Duration

Unknown — chronic administration presumed in animal models

10-day cycles, 1–2× per year

Half-life

Not reported

Hours

Lower / starter dose

—

2.5 mg / day

Reconstitution

—

Bacteriostatic water

Timing

—

No specific time

04Side Effects & Safety

Parameter

Crystagen

Pinealon

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Injection site reaction

—

Mild irritation

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

Pinealon

·Pregnancy / breastfeeding

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

Pinealon

·Active malignancy (theoretical via gene expression modulation)

05Administration Protocol

Parameter

Crystagen

Pinealon

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Add 1–2 mL bacteriostatic water to 10 mg vial.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

SQ — abdomen preferred.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Daily during cycle, any time.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003